Oculis to Spotlight Innovative Developments at H.C. Wainwright Conference
Oculis Holding AG (NASDAQ: OCS) is set to showcase its advancements in the biopharmaceutical field as it participates in the upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. The company focuses on groundbreaking innovations aimed at treating ophthalmic and neuro-ophthalmic conditions, addressing significant unmet needs in medical care.
Key Presentations and Participation Highlights
During the conference, Oculis will feature presentations from its leadership team, including Sylvia Cheung, Chief Financial Officer, who will provide a detailed corporate update. This presentation is scheduled for 7:00 AM ET and will be available for replay via webcast. Attendees can expect insights into the company's strategic direction and updates on ongoing clinical efforts.
Additionally, Snehal Shah, the President of Research and Development at Oculis, will partake in a live panel discussion focused on pivotal-stage assets for retinal disorders. This discussion, which runs from 11:00 AM to 12:00 PM ET, will be valuable for those interested in the latest developments in retinal therapies.
Accessing Conference Resources
The corporate update presentation and panel discussion will be accessible via Oculis' dedicated section for Events and Presentations on their official website. This offers a fantastic opportunity for investors and stakeholders to gain deeper insights into the conference discussions and what the company has planned for the future.
About Oculis Holding AG
Oculis is at the forefront of advancing treatment options within the ophthalmic sector. The company’s late-stage clinical pipeline features three main product candidates: OCS-01, currently in pivotal registration studies, aims to deliver the first non-invasive topical treatment for diabetic macular edema. Privosegtor (OCS-05) is designed to provide neuroprotection for acute optic neuritis and other various neuro-ophthalmic conditions. Finally, Licaminlimab (OCS-02), a novel anti-TNF? topical treatment, is being developed to personalize medicine for dry eye disease, utilizing a genotype-based approach.
Oculis' Commitment and Vision
With its headquarters in Switzerland and operations extending to the U.S. and Iceland, Oculis demonstrates a firm commitment to transforming the management of eye diseases through innovation and research. The company’s leadership team is renowned for its expertise and has cultivated a dynamic environment for growth, supported by prominent healthcare investors.
For those wishing to learn more about Oculis and its pioneering initiatives, detailed information can be found on their official website, providing a comprehensive overview of their ongoing projects and commitment to delivering impactful solutions in ophthalmology.
Oculis Contacts
For additional inquiries, interested parties can contact:
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com
Frequently Asked Questions
What is the focus of Oculis Holding AG?
Oculis focuses on developing innovative treatments for ophthalmic and neuro-ophthalmic conditions, addressing unmet medical needs.
When is the H.C. Wainwright conference scheduled?
The conference is scheduled, with Oculis participating on August 13, 2025.
Who is presenting at the Oculis session?
Sylvia Cheung, CFO, and Snehal Shah, President of R&D, are key presenters at the conference.
How can I access the Oculis presentations?
The presentations will be available for replay on the Oculis website under the Events & Presentations section.
Where is Oculis headquartered?
Oculis is based in Switzerland, with operations in the U.S. and Iceland.
